Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AT-101 with Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma
NCT02697344Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- Apr 2016
- Primary completion
- Oct 2018
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of r-(-)-gossypol acetic acid in multiple myeloma (MM), sponsored by Mayo Clinic. Primary endpoints: Maximum Tolerated Dose and Overall Response Rate up to 3 years. Started Apr 2016; status: completed.
02
Drugs
r-(-)-gossypol acetic acid
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02697344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02697344.